Clinical Research Directory
Browse clinical research sites, groups, and studies.
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer
Sponsor: Centre Antoine Lacassagne
Summary
RATIONALE: Identifying genes that increase a person's susceptibility to side effects caused by capecitabine may help doctors plan better treatment. PURPOSE: This clinical trial is studying blood samples in predicting response to capecitabine in women with metastatic breast cancer.
Official title: Multicentric Pilot Study of Dihydropyrimidine Dehydrogenase (DPD) Deficiency for Predicting Capecitabine Toxicity in Breast Cancer Patients
Key Details
Gender
FEMALE
Age Range
18 Years - 120 Years
Study Type
INTERVENTIONAL
Enrollment
303
Start Date
2009-01
Completion Date
2011-02
Last Updated
2026-05-05
Healthy Volunteers
No
Conditions
Interventions
capecitabine
laboratory biomarker analysis
pharmacological study
Locations (1)
Centre Antoine Lacassagne
Nice, France